Detection strategies for elevated lipoprotein(a): Will implementation let the genie out of the bottle?

Research output: Contribution to journalReview articlepeer-review


Purpose of review Elevated Lp(a) level is an important causal risk factor for atherosclerotic cardiovascular disease (ASCVD), principally coronary artery disease. Selective testing for Lp(a) is highly recommended in patients at intermediate and high risk for ASCVD. Lp(a) levels are predominantly genetically determined, and this has implications for cascade testing.Recent findingsRecent studies show that cascade testing is effective in identifying elevated Lp(a) in close relatives of probands with high Lp(a). Apart from selective testing and cascade testing as detection strategies, some recent guidelines recommend testing of Lp(a) in all adults at least once in their lifetime and various implementation strategies have been suggested.SummaryHyper-Lp(a) is an important global health problem that can be easily detected. Hyper-Lp(a) meets all the criteria for universal screening except that there is not yet supportive evidence from clinical interventional trials showing a reduction of ASCVD events. The cost-effectiveness of the various detection and implementation strategies need to be further evaluated.

Original languageEnglish
Pages (from-to)94-102
Number of pages9
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Issue number2
Publication statusPublished - 1 Apr 2023

Cite this